DOCSLIB.ORG

Effect of Eritoran, an Antagonist of MD2-TLR4, on Mortality in Patients with Severe Sepsis the ACCESS Randomized Trial

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Effect of Eritoran, an Antagonist of MD2-TLR4, on Mortality in Patients with Severe Sepsis the ACCESS Randomized Trial CARING FOR THE CRITICALLY ILL PATIENT Effect of Eritoran, an Antagonist of MD2-TLR4, on Mortality in Patients With Severe Sepsis The ACCESS Randomized Trial Steven M. Opal, MD Importance Eritoran is a synthetic lipid A antagonist that blocks lipopolysaccharide Pierre-Francois Laterre, MD (LPS) from binding at the cell surface MD2-TLR4 receptor. LPS is a major component Bruno Francois, MD of the outer membrane of gram-negative bacteria and is a potent activator of the acute inflammatory response. Steven P. LaRosa, MD Objective To determine if eritoran, a TLR4 antagonist, would significantly reduce Derek C. Angus, MD, MPH sepsis-induced mortality. Jean-Paul Mira, MD, PhD Design, Setting, and Participants We performed a randomized, double-blind, Xavier Wittebole, MD placebo-controlled, multinational phase 3 trial in 197 intensive care units. Patients were enrolled from June 2006 to September 2010 and final follow-up was completed in Thierry Dugernier, MD September 2011. Dominique Perrotin, MD Interventions Patients with severe sepsis (n=1961) were randomized and treated Mark Tidswell, MD within 12 hours of onset of first organ dysfunction in a 2:1 ratio with a 6-day course of either eritoran tetrasodium (105 mg total) or placebo, with n=1304 and n=657 Luis Jauregui, MD patients, respectively. Kenneth Krell, MD Main Outcome Measures The primary end point was 28-day all-cause mortality. Jan Pachl, MD The secondary end points were all-cause mortality at 3, 6, and 12 months after be- Takeshi Takahashi, MD ginning treatment. Claus Peckelsen, MD Results Baseline characteristics of the 2 study groups were similar. In the modified intent-to-treat analysis (randomized patients who received at least 1 dose) there was Edward Cordasco, DO no significant difference in the primary end point of 28-day all-cause mortality with Chia-Sheng Chang, MD 28.1% (366/1304) in the eritoran group vs 26.9% (177/657) in the placebo group (P=.59; hazard ratio, 1.05; 95% CI, 0.88-1.26; difference in mortality rate, Ϫ1.1; 95% Sandra Oeyen, MD CI, Ϫ5.3 to 3.1) or in the key secondary end point of 1-year all-cause mortality with Naoki Aikawa, MD, PhD 44.1% (290/657) in the eritoran group vs 43.3% (565/1304) in the placebo group, Tatsuya Maruyama, MD, PhD Kaplan-Meier analysis of time to death by 1 year, P=.79 (hazard ratio, 0.98; 0.85- 1.13). No significant differences were observed in any of the prespecified subgroups. Roland Schein, MD Adverse events, including secondary infection rates, did not differ between study groups. Andre C. Kalil, MD, MPH Conclusions and Relevance Among patients with severe sepsis, the use of eri- Marc Van Nuffelen, MD toran, compared with placebo, did not result in reduced 28-day mortality. Melvyn Lynn, PhD Trial Registration clinicaltrials.gov Identifier: NCT00334828 JAMA. 2013;309(11):1154-1162 www.jama.com Daniel P. Rossignol, PhD Jogadish Gogate, PhD Author Affiliations are listed at the end of this ar- EVERE SEPSIS, A SYNDROME OF Mary B. Roberts, MS ticle. acute infection complicated by Corresponding Author: Steven M. Opal, MD, Divi- Janice L. Wheeler, BS, RN sion of Infectious Diseases, Memorial Hospital of organ dysfunction, is caused by Rhode Island, 111 Brewster St, Pawtucket, RI 02860 Jean-Louis Vincent, MD, PhD a dysregulated systemic inflam- ([email protected]) Smatory response. Sepsis can progress to Caring for the Critically Ill Patient Section Editor: Derek for the ACCESS Study Group C. Angus, MD, MPH, Contributing Editor, JAMA systemic hypotension (septic shock), ([email protected]). 1154 JAMA, March 20, 2013—Vol 309, No. 11 ©2013 American Medical Association. All rights reserved. Corrected on March 19, 2013 Downloaded From: http://jama.jamanetwork.com/ by a University of Gent / UZGent Kenniscentrum User on 03/26/2013 ERITORAN FOR THE TREATMENT OF SEVERE SEPSIS manifest by hypoperfusion of vital or- non-Japanese; Japanese; other; His- throughout the study. The clinical gans, multiple organ dysfunction, and panic, non-Hispanic) were noted at evaluation committee determined the death.1-3 screening for planned subgroup analy- type, site, and causative organism of The Surviving Sepsis Campaign re- ses of efficacy and safety. Racial cat- sepsis-defining infections. ported decreased mortality based on im- egories were self-reported and these dif- proved supportive care and evidence- ferences were assessed to determine if Study Procedures based guidelines for diagnosis and TLR4 polymorphisms from different A total dose of 98.41 mg eritoran (free timely intervention.4,5 However, mor- populations affected responsiveness to acid) was administered. This amount is tality remains at approximately 30%4 eritoran therapy. equal to the highest total dose of eri- and hospital admissions for severe sep- toran tetrasodium (105 mg) used in the sis have increased.3,5,6 Thus, improve- Patient Selection phase 2 severe sepsis study.15 Eritoran ments in care for severe sepsis remain Patients who were at least 18 years old was administered intravenously as a load- a priority. with early severe sepsis or septic shock ing dose of 26.24 mg (6.56 mg/h for 4 Lipopolysaccharide (LPS) or endo- and high risk of death were screened for hours), followed by a second loading toxin, the major component of the outer participation. Severe sepsis was de- dose of 13.12 mg (6.56 mg/h for 2 hours) membrane of gram-negative bacteria, is fined as documented evidence of bac- 12 hours later, and 9 maintenance doses a potent stimulator of the inflamma- terial or fungal infection, at least 3 cri- of 6.56 mg (3.28 mg/h for 2 hours) given tory response.7 LPS triggers inflamma- teria for systemic inflammatory response every 12 hours thereafter. Matching pla- tion in gram-negative sepsis. Exces- syndrome (SIRS eAppendix, available at cebo (vehicle) vials, with identical re- sive amounts of gut-derived LPS http://www.jama.com), and at least 1 constitution and infusion instructions to released during intestinal hypoperfu- major organ dysfunction. Septic shock the eritoran vials, were administered on sion are implicated in sepsis caused by was defined as hypotension requiring va- the same schedule. gram-positive and fungal infections.8,9 sopressors (eAppendix). High risk of LPS signaling is initiated by activa- death was defined as having an APACHE Primary and Secondary Outcomes tion of the MD2:toll-like receptor 4 II (Acute Physiology and Chronic Health Survival was ascertained at 28 days (TLR4) on myeloid cells.7,10 Eritoran Evaluation) score of at least 21 and not after beginning treatment (the pri- (E5564), a synthetic analog of lipid A greater than 37. The onset of the first mary outcome measure) and at 3, 6, and a potent and specific antagonist of sepsis-related organ dysfunction had to and 12 months through interviews LPS action, inhibits lipid A binding to occur less than 12 hours before admin- with patients or surrogates. Serum MD2 and terminates MD2/TLR4- istration of the study drug. Key exclu- samples of inflammatory markers mediated signaling invitro, exvivo, and sion criteria are listed in eAppendix. were obtained at baseline, 30 minutes invivo.11-13 In a phase 1 trial, eritoran before the second loading dose, and blocked cytokine responses and clini- Randomization on days 2 and 3. When not normally cal illness in healthy volunteers14 and Eligible patients were assigned by cen- distributed, log-transformation of in a phase 2 trial, eritoran-treated pa- tralized randomization using a com- these data was performed for statisti- tients at high risk of death had lower puterized set of random numbers in a cal analysis. Endotoxin activity assays mortality that was not statistically sig- 2:1 eritoran:placebo ratio. Patients were were performed at baseline in a subset nificant (eritoran 37.5% vs placebo assessed daily until hospital discharge of patients by previously described 56.3%).15 or day 28 after randomization. Long- methods (eAppendix).9 The current trial evaluated the safety term follow-up evaluations occurred at Eritoran efficacy was evaluated in and efficacy of eritoran in reducing mor- 3, 6, and 12 months. prespecified patient subpopulations de- tality in patients with severe sepsis. Critical care and infectious disease fined as follows: baseline APACHE II specialists at 3 clinical coordinating cen- score groups (21-24, Ͼ24-26, Ͼ26- METHODS ters (United States, Belgium, and Ja- 31, and Ͼ31-37); gram-negative vs The ACCESS (a controlled compari- pan) reviewed all screening data with gram-positive infections; infection sites son of eritoran and placebo in patients study sites before enrollment to con- (lung, abdomen, genitourinary, skin/ with severe sepsis) trial was designed firm that patients met all inclusion but soft tissue, primary and catheter- as a randomized, double-blind, placebo- no exclusion criteria. Approval from in- related bacteremia, central nervous sys- controlled, phase 3 clinical study. En- stitutional review or ethics boards was tem, and other); and baseline severity rollment occurred from June 2006 obtained for all sites, and written in- of illness by Sequential Organ Failure through September 2010 in 197 sites formed consent was obtained from all Assessment (SOFA) scores. in North America, Europe, South patients or proxies as required by lo- America, Africa, Asia, and Australia. cal authorities. A clinical evaluation Safety Measures Predefined race and ethnicity informa- committee (eAppendix) performed Electrocardiograms, laboratory mea- tion categories (white; black; Asian, blinded evaluations of procedures surements, and physical examina- ©2013 American Medical Association. All rights reserved. JAMA, March 20, 2013—Vol 309, No. 11 1155 Corrected on March 19, 2013 Downloaded From: http://jama.jamanetwork.com/ by a University of Gent / UZGent Kenniscentrum User on 03/26/2013 ERITORAN FOR THE TREATMENT OF SEVERE SEPSIS tions were performed throughout the Infection-related adverse events were Statistical Analysis active 28-day follow-up period or at closely monitored to assess the poten- A modified intent-to-treat (MITT) hospital discharge.
Load more

Recommended publications
  • 1 Combined Effect of Anti-High-Mobility Group Box-1 Monoclonal Antibody and Peramivir Against Influenza a Virus-Induced Pneumoni
    Combined effect of anti-high-mobility group box-1 monoclonal antibody and peramivir against influenza A virus-induced pneumonia in mice Kazuki Hatayama1; Nobuyuki Nosaka1*; Mutsuko Yamada1; Masato Yashiro1; Yosuke Fujii1; Hirokazu Tsukahara1; Keyue Liu3; Masahiro Nishibori3; Akihiro Matsukawa4; Tsuneo Morishima1,2 1 Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan 2 Department of Pediatrics, Aichi Medical University, Japan 3 Department of Pharmacology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan 4 Department of Pathology and Experimental Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan 1 *Correspondence author: Nobuyuki Nosaka 2-5-1 Shikata-cho, Kita-ku, Okayama city, Okayama pref. 700-8558, Japan Tel: +81-86-235-7249 Email: [email protected] Shortened title: Anti-HMGB1 plus peramivir for influenza 2 ABSTRACT Human pandemic H1N1 2009 influenza virus causes significant morbidity and mortality with severe acute lung injury (ALI) due to excessive inflammatory reaction, even with neuraminidase inhibitor use. The anti-inflammatory effect of anti-high-mobility group box-1 (HMGB1) monoclonal antibody (mAb) against influenza pneumonia has been reported. In this study, we evaluated the combined effect of anti-HMGB1 mAb and peramivir against pneumonia induced by influenza A (H1N1) virus in mice. Nine-week-old male C57BL/6 mice were inoculated with H1N1 and treated with intramuscularly administered peramivir at 2 and 3 days post-infection (dpi). The anti-HMGB1 mAb or a control mAb was administered at 2, 3, and 4 dpi. Survival rates were assessed, and lung lavage and pathological analyses were conducted at 5 and 7 dpi.
    [Show full text]
  • Improving Pipeline for the Development of Influenza Antivirals
    United States Department of Health & Human Services Office of the Assistant Secretary for Preparedness and Response Improving Pipeline for the Development of Influenza Antivirals Michael W Wathen, Ph.D. Chief, Antiviral Advanced Development Influenza Division BARDA BARDA Influenza Antiviral Program Strategy Overview National Strategy Issues BARDA Strategy ASPR: Resilient People. Healthy Communities. A Nation Prepared. 2 Issues for Influenza Antivirals • Current therapies have narrow treatment window ─ Treatment within 48h of symptom onset for neuraminidase inhibitors ─ Can treatment window be expanded with novel antivirals having different mechanisms of action? • Constant threat of resistance ─ Value of M-2 blockers minimized by resistance ─ Heavy reliance on neuraminidase inhibitors ─ Few combination therapies unavailable • Limited options in U.S. for special populations ─ No IV formulations approved for patients on ventilators ─ No drugs approved for severely ill, hospitalized patients ─ Limited treatment options for pediatric patients ASPR: Resilient People. Healthy Communities. A Nation Prepared. 3 BARDA Influenza Antiviral Program Advanced Development Strategy 2005 National Strategy for Pandemic Influenza • Accelerate development, evaluation, approval and U.S.-based production of new influenza antiviral drugs Treatment Gap Issues • Special populations (pediatrics, severely ill hospitalized) Existing BARDA Advanced Development Projects • Fill critical unmet medical needs by expanding the utility of neuraminidase inhibitors •Peramivir •$235M contract with BioCryst awarded in 2007 •Development of IV peramivir in hospitalized patients •EUA designated by FDA during 2009 pandemic •First unapproved drug authorized for use under an EUA •Worldwide clinical program for licensure in U.S. •Laninamivir •$231M contract with Biota awarded in 2011 •Development of inhaled laninamivir in outpatient setting •Single-dose treatment course ASPR: Resilient People.
    [Show full text]
  • Hydrophobic Amino-Terminal Pocket CD14 Reveals a Bent Solenoid with a the Crystal Structure of Human Soluble
    The Crystal Structure of Human Soluble CD14 Reveals a Bent Solenoid with a Hydrophobic Amino-Terminal Pocket This information is current as Stacy L. Kelley, Tiit Lukk, Satish K. Nair and Richard I. of September 25, 2021. Tapping J Immunol 2013; 190:1304-1311; Prepublished online 21 December 2012; doi: 10.4049/jimmunol.1202446 http://www.jimmunol.org/content/190/3/1304 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2012/12/31/jimmunol.120244 Material 6.DC1 http://www.jimmunol.org/ References This article cites 87 articles, 45 of which you can access for free at: http://www.jimmunol.org/content/190/3/1304.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision by guest on September 25, 2021 • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2013 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology The Crystal Structure of Human Soluble CD14 Reveals a Bent Solenoid with a Hydrophobic Amino-Terminal Pocket Stacy L.
    [Show full text]
  • Advancing the Development Pipeline for the Treatment of Influenza
    United States Department of Health & Human Services Office of the Assistant Secretary for Preparedness and Response Advancing the Development Pipeline for the Treatment of Influenza Melissa Willis, Ph.D. Chief, Influenza Therapeutics Influenza Division BARDA Roadmap • What is our goal? • Where have we been? • Where are we going? • Why now? • What strategies we are pursuing to achieve the goal? ASPR: Resilient People. Healthy Communities. A Nation Prepared. 2 BARDA Influenza Antiviral Program Program Goal “Reduce morbidity and mortality in all patient populations during an influenza pandemic by supporting advanced development, evaluation, and approval of new influenza antiviral drugs” • Mission established in the 2005 National Strategy for Pandemic Influenza, HHS Pandemic Influenza Plan and the 2006 Implementation Plan for the National Strategy for Pandemic Influenza • Initial stockpiling goal and advanced development projects • Stockpile total of 81M treatment courses of influenza antiviral drugs • Advanced development of new antiviral drugs • New BARDA advanced development projects are focused on developing drugs to address critical unmet needs in treating severely ill, hospitalized patients and in pediatric populations • Novel mechanisms of action • Combination therapy Our total reliance on monotherapy with NAI’s has placed us at risk of no treatment options to ASPR:address Resilient a potentialPeople. Healthy NAI- resistantCommunities. pandemic A Nation Prepared. 3 BARDA Influenza Therapeutics Program Line-Up • Two large, full development
    [Show full text]
  • TLR4 Signaling Pathway Modulators As Potential Therapeutics in Inflammation and Sepsis
    vaccines Review TLR4 Signaling Pathway Modulators as Potential Therapeutics in Inflammation and Sepsis Nikolay N. Kuzmich 1,2,*, Konstantin V. Sivak 1, Vladimir N. Chubarev 3, Yury B. Porozov 2,4, Tatiana N. Savateeva-Lyubimova 1 and Francesco Peri 5,* ID 1 Department of Drug Safety, Research Institute of Influenza, WHO National Influenza Centre of Russia, 15/17 Professor Popov St, Saint-Petersburg 197376, Russia; [email protected] (K.V.S.); [email protected] (T.N.S.-L.) 2 Laboratory of Bioinformatics, Institute of Pharmacy and Translational medicine, I.M. Sechenov First Moscow State Medical University, 8-2 Trubetskaya St., Moscow 119991, Russia; [email protected] 3 Department of Pharmacology, Institute of Pharmacy and Translational medicine, I.M. Sechenov First Moscow State Medical University, 8-2 Trubetskaya St., Moscow 119991, Russia; [email protected] 4 Laboratory of Bioinformatics, ITMO University, 49 Kronverkskiy Pr., Saint Petersburg 197101, Russia 5 Department of Biotechnology and Biosciences, University of Milano-Bicocca, Piazza della Scienza 2, Milano 20126, Italy * Correspondence: [email protected] (N.N.K.); Tel.: +7-921-3491-750 (N.N.K.); [email protected] (F.P.); Tel.: +39-026-448-3453 (F.P.); Fax: +7-812-499-15-15 (N.N.K.) Academic Editor: Paola Massari Received: 5 September 2017; Accepted: 1 October 2017; Published: 4 October 2017 Abstract: Toll-Like Receptor 4 (TLR4) signal pathway plays an important role in initiating the innate immune response and its activation by bacterial endotoxin is responsible for chronic and acute inflammatory disorders that are becoming more and more frequent in developed countries.
    [Show full text]
  • TLR4-Targeting Therapeutics: Structural Basis and Computer-Aided Drug Discovery Approaches
    molecules Review TLR4-Targeting Therapeutics: Structural Basis and Computer-Aided Drug Discovery Approaches Qurat ul Ain, Maria Batool and Sangdun Choi * Department of Molecular Science and Technology, Ajou University, Suwon 16499, Korea; [email protected] (Q.u.A.); [email protected] (M.B.) * Correspondence: [email protected]; Tel.: +82-31-219-2600; Fax: +82-31-219-1615 Academic Editor: Julio Caballero Received: 5 January 2020; Accepted: 29 January 2020; Published: 31 January 2020 Abstract: The integration of computational techniques into drug development has led to a substantial increase in the knowledge of structural, chemical, and biological data. These techniques are useful for handling the big data generated by empirical and clinical studies. Over the last few years, computer-aided drug discovery methods such as virtual screening, pharmacophore modeling, quantitative structure-activity relationship analysis, and molecular docking have been employed by pharmaceutical companies and academic researchers for the development of pharmacologically active drugs. Toll-like receptors (TLRs) play a vital role in various inflammatory, autoimmune, and neurodegenerative disorders such as sepsis, rheumatoid arthritis, inflammatory bowel disease, Alzheimer’s disease, multiple sclerosis, cancer, and systemic lupus erythematosus. TLRs, particularly TLR4, have been identified as potential drug targets for the treatment of these diseases, and several relevant compounds are under preclinical and clinical evaluation. This review covers the reported computational studies and techniques that have provided insights into TLR4-targeting therapeutics. Furthermore, this article provides an overview of the computational methods that can benefit a broad audience in this field and help with the development of novel drugs for TLR-related disorders.
    [Show full text]
  • A Meeting Report from the 6Th Isirv Antiviral Group Conference T
    Antiviral Research 167 (2019) 45–67 Contents lists available at ScienceDirect Antiviral Research journal homepage: www.elsevier.com/locate/antiviral Advances in respiratory virus therapeutics – A meeting report from the 6th isirv Antiviral Group conference T ∗ John H. Beigela, , Hannah H. Namb, Peter L. Adamsc, Amy Kraffta, William L. Inced, Samer S. El-Kamaryd, Amy C. Simse a National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA bNorthwestern University, Feinberg School of Medicine, Chicago, IL, USA c Biomedical Advanced Research and Development Authority (BARDA), Office of the Assistant Secretary for Preparedness and Response (ASPR), Department of Health and Human Services (HHS), Washington, DC, USA d Division of Antiviral Products, Office of Antimicrobial Products, Office of New Drugs, Center for Drug Evaluation and Research, U.S Food and Drug Administration, Silver Spring, MD, USA e Gillings School of Global Public Health, Department of Epidemiology, University of North Carolina, Chapel Hill, NC, USA ARTICLE INFO ABSTRACT Keywords: The International Society for Influenza and other Respiratory Virus Diseases held its 6th Antiviral Group (isirv- Influenza AVG) conference in Rockville, Maryland, November 13–15, 2018. The three-day program was focused on Respiratory syncytial virus therapeutics towards seasonal and pandemic influenza, respiratory syncytial virus, coronaviruses including Coronavirus MERS-CoV and SARS-CoV, human rhinovirus, and other respiratory viruses. Updates were presented on several Antiviral therapy influenza antivirals including baloxavir, CC-42344, VIS410, immunoglobulin, immune plasma, MHAA4549A, Host-directed therapeutics pimodivir (JNJ-63623872), umifenovir, and HA minibinders; RSV antivirals including presatovir (GS-5806), ziresovir (AK0529), lumicitabine (ALS-008176), JNJ-53718678, JNJ-64417184, and EDP-938; broad spectrum antivirals such as favipiravir, VH244, remdesivir, and EIDD-1931/EIDD-2801; and host directed strategies in- cluding nitazoxanide, eritoran, and diltiazem.
    [Show full text]
  • Low-Dose Naltrexone/Acetaminophen
    medRxiv preprint doi: https://doi.org/10.1101/2021.03.22.21254145; this version posted March 24, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . 1 Low-Dose Naltrexone/Acetaminophen Combinations and Each Component in the Acute Treatment of Migraine: Findings of a Small, Randomized, Double- Blind, and Placebo-Controlled Clinical Trial Annette C. Toledano, M.D.1 1 Sponsor/investigator. Founder/medical director, Allodynic Therapeutics, LLC, North Miami, Florida. Corresponding author: Annette Toledano, M.D. E-mail: [email protected] Phone: 305 895 6808 ABSTRACT We tested two low-dose naltrexone/acetaminophen combinations and each component in the acute treatment of migraine. The patients use a single-dose of the study medication for a moderate or severe pain intensity migraine attack. Patients were adults with migraine with or without aura experiencing 2 to 20 (average 6.4) monthly migraine days. The co-primary endpoints were pain-freedom and absence of prospectively- identified most bothersome migraine-associated symptom 2 hours after dosing. We randomized 92 patients; 72 completed the study (mean age, 43 years; 75% women). Pain-freedom at 2 hours was 10.2% higher than placebo with naltrexone 2.25 mg/acetaminophen 325 mg, 10.9% with naltrexone 3.25 mg/acetaminophen 325 mg, NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
    [Show full text]
  • Antivirals - Influenza
    Antivirals - Influenza There are two principal classes of antivirals licensed for prophylaxis and treatment of influenza, those targeted against the M2 proton channel and those against the neuraminidase. An inhibitors of the membrane fusion activity of the HA is licensed in a number of countries, and an inhibitor of the RNA polymerase has recently received a restricted license. Amantadine (Symmetrel®), developed in the 1960s, and rimantadine (Flumadine®) inhibit the function of the M2 protein of influenza A in virus uncoating, but are not effective against influenza B. They have not been widely used and resistance of currently circulating A(H1N1)pdm09 and A(H3N2) viruses has removed their usefulness against seasonal influenza. Zanamivir (Relenza®) and oseltamivir (Tamiflu®) were developed in the 1990s against the neuraminidase, which is involved in the release and spread of progeny virus. They are effective against both influenza A and B viruses, and are widely available. Whereas zanamivir is administered by inhalation, oseltamivir is administered orally and has proved to be more widely accepted, and has been the principal choice for antiviral stockpiles as a component of pandemic preparedness. However resistance to oseltamivir has occurred more frequently than resistance to zanamivir. Two other neuraminidase inhibitors have been licensed more recently: laninamivir (Inavir®) a long-lasting analogue of zanamivir, administered by inhalation as a single therapeutic dose, has been licensed in Japan; peramivir, which possesses the active moieties of both zanamivir and oseltamivir, has been licensed in Japan (Rapiacta®) and Korea (PeramiFlu®) for intravenous administration. Arbidol falls within a third class of antivirals, which targets the membrane fusion activity of the HA in vitro.
    [Show full text]
  • Lipid and Lipoprotein Dysregulation in Sepsis: Clinical and Mechanistic Insights Into Chronic Critical Illness
    Journal of Clinical Medicine Review Lipid and Lipoprotein Dysregulation in Sepsis: Clinical and Mechanistic Insights into Chronic Critical Illness Grant Barker 1, Christiaan Leeuwenburgh 2, Todd Brusko 3 , Lyle Moldawer 4, Srinivasa T. Reddy 5 and Faheem W. Guirgis 1,* 1 Department of Emergency Medicine, College of Medicine-Jacksonville, University of Florida, 655 West 8th Street, Jacksonville, FL 32209, USA; [email protected]fl.edu 2 Department of Aging and Geriatric Research, College of Medicine, University of Florida, Gainesville, FL 32603, USA; cleeuwen@ufl.edu 3 Department of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida Diabetes Institute, Gainesville, FL 32610, USA; tbrusko@ufl.edu 4 Department of Surgery, College of Medicine, University of Florida, Gainesville, FL 32608, USA; [email protected]fl.edu 5 Division of Cardiology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA; [email protected] * Correspondence: [email protected]fl.edu; Tel.: +1-904-244-4986 Abstract: In addition to their well-characterized roles in metabolism, lipids and lipoproteins have pleiotropic effects on the innate immune system. These undergo clinically relevant alterations during sepsis and acute inflammatory responses. High-density lipoprotein (HDL) plays an important role in regulating the immune response by clearing bacterial toxins, supporting corticosteroid release, decreasing platelet aggregation, inhibiting endothelial cell apoptosis, reducing the monocyte inflam- Citation: Barker, G.; Leeuwenburgh, matory response, and inhibiting expression of endothelial cell adhesion molecules. It undergoes C.; Brusko, T.; Moldawer, L.; Reddy, quantitative as well as qualitative changes which can be measured using the HDL inflammatory index S.T.; Guirgis, F.W.
    [Show full text]
  • The Preventive Treatment of Migraine with Low-Dose Naltrexone And
    medRxiv preprint doi: https://doi.org/10.1101/2021.03.23.21254186; this version posted April 12, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . 1 The Preventive Treatment of Migraine with Low- Dose naltrexone and acetaminophen Combination: Findings of a Small, Randomized, Double-Blind, and Placebo-Controlled Clinical Trial with an Open-Label Extension for None-Responders Annette C. Toledano1 1 Sponsor/investigator. Founder/medical director, Allodynic Therapeutics, LLC, North Miami, Florida. Corresponding author: Annette Toledano, M.D. E-mail: [email protected] Phone: 305 895 6808 ABSTRACT We tested a low-dose naltrexone and acetaminophen combination for episodic migraine prevention. We randomly assigned patients to naltrexone and acetaminophen combination (n=6) or placebo (n=6) for a 12-week double-blind treatment. Non- responders continued into open-label treatment with naltrexone and acetaminophen combination (n=5) for additional 12 weeks. Patients were adults who experienced 5 to 17 (average 9.7) migraine days at baseline. The primary endpoint was the mean change in the monthly migraine days during the last 4 weeks of the double-blind treatment period. The key secondary endpoint was the mean change in the monthly NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2021.03.23.21254186; this version posted April 12, 2021.
    [Show full text]
  • For Print （17KB）
    4-6-10 Koishikawa, Bunkyo-ku, Tokyo 112-8088 , Japan Eisai Co., Ltd. Phone: 03- 3817-5120 Fax: 03- 3811-3077 Eisai is a Human Health Care Corporation striving for innovative solutions in prevention, cure and care for the health and well-being of people worldwide. We combine our talents to understand and meet the needs of patients and their families to enhance the quality of life. FOR IMMEDIATE RELEASE No.10-10 March 26, 2010 Eisai Co., Ltd. Eisai to Continue Eritoran (E5564) Phase III Severe Sepsis Trial Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito) announced today that an independent Data Monitoring Committee (DMC), which met on March 25 (United Kingdom local time), has recommended the Company continue enrolment to the preset goal of 2,000 patients in the Phase III ACCESS (A Controlled Comparison of Eritoran and Placebo in Patients with Severe Sepsis) trial, an Eisai global clinical development programme of the investigational compound eritoran (E5564) for severe sepsis. This recommendation was made based on a planned interim analysis evaluating safety and efficacy data from the ACCESS trial for the first 1,500 patients. In addition, the DMC did not express safety concerns that would warrant stopping the trial at this time. In accordance with the DMC’s recommendation, Eisai will continue enrolment to the planned goal of 2,000 patients in the trial. Sepsis is a serious condition with an extreme systemic inflammatory response to infection. In severe cases, the mortality is very high due to the onset of septic shock, disseminated intravascular coagulation and organ dysfunction lead to high mortality.
    [Show full text]